Prolotherapy Versus Epidural Steroid Injections (ESI) for Lumbar Pain Radiating to the Leg (NCT01934868) | Clinical Trial Compass
CompletedPhase 4
Prolotherapy Versus Epidural Steroid Injections (ESI) for Lumbar Pain Radiating to the Leg
Israel110 participantsStarted 2013-12-01
Plain-language summary
The hypothesis is that in the treatment of low back pain (LBP) radiating to the leg, the long-term results of prolotherapy are more effective than those of the current conventional treatment: epidural steroid injections (ESI). This research will examine the efficacy of prolotherapy injections versus epidural steroid injections for the treatment of low back pain radiating to the leg. This is a randomized, unblinded study, in which patients seen in the principle investigator's pain clinic will be randomly divided to receive treatments from either the experimental, prolotherapy group, or the active control, ESI group.
Who can participate
Age range18 Years – 90 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Pain radiating down one or both legs or to the groin of at least 12 weeks' duration
* Patients with disc lesions with radiating pain to the leg(s)
* Mild spinal stenosis
Exclusion Criteria:
* History of back surgery
* Recent history (less than 2 years) of active malignancy
* Recent fracture in the lumbar spine or pelvis of less than 12 months
* Active locus of infection in the body
* Coagulation disorders, and current anticoagulation therapy, excluding aspirin
* Chronic medication with corticosteroids and NSAIDS (which are said to possibly neutralise the effect of prolotherapy) - the latter must be stopped 24 hours prior to the first treatment session
* Recent injection of cortisone for back pain or any other pathology elsewhere in the body- patients must wait 2 weeks before commencement of the study
* Concurrent significant depressive illness or evidence of catastrophisation, fibromyalgia
* Concurrent history of active autoimmune disease or inflammatory joint disease evidence of a peripheral neuropathy
NOTE:
If any of the above illnesses appear during the time of the treatment in any patient, the patient will be withdrawn from the trial as treatment may be detrimental to his or her health. In addition, follow-up is not relevant to compare a diseased patient with any of the above with patients who are free of the above illnesses.